Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Oct 18;2006(4):CD003489.
doi: 10.1002/14651858.CD003489.pub2.

Malaria chemoprophylaxis in sickle cell disease

O Oniyangi  1 , A A A Omari
Affiliations

Malaria chemoprophylaxis in sickle cell disease

O Oniyangi et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Malaria is the most common precipitating cause of crises in sickle cell disease in malaria-endemic countries. Health professionals often recommend life-long malaria chemoprophylaxis for people with sickle cell disease living in these areas. It is therefore important we have good evidence of benefit.

Objectives: To assess the effects of routine malaria chemoprophylaxis in people with sickle cell disease.

Search strategy: We searched the Cochrane Infectious Diseases Group Specialized Register (January 2006), Cochrane Cystic Fibrosis and Genetic Disorders Group Specialized Register (July 2006), CENTRAL (The Cochrane Library 2006, Issue 1), MEDLINE (1966 to January 2006), EMBASE (1974 to January 2006), LILACS (1982 to January 2006), and reference lists. We also contacted organizations and pharmaceutical companies.

Selection criteria: Randomized and quasi-randomized controlled trials comparing chemoprophylaxis with any antimalarial drug given for a minimum of three months compared with a placebo or no intervention.

Data collection and analysis: Two authors independently applied the inclusion criteria, assessed methodological quality, and extracted data. Dichotomous data were analysed using relative risks (RR) and presented with 95% confidence intervals (CI).

Main results: Two trials with a total of 223 children with homozygous sickle cell disease met the inclusion criteria. A randomized controlled trial in Nigeria compared two different antimalarial drugs with a placebo, and reported that chemoprophylaxis reduced sickle cell crises (RR 0.17, 95% CI 0.04 to 0.83; 97 children), hospital admissions (RR 0.27, 95% CI 0.12 to 0.63; 97 participants), and blood transfusions (RR 0.16, 95% CI 0.05 to 0.56; 97 participants). A quasi-randomized controlled trial of 126 children in Uganda compared an antimalarial drug plus antibiotics with no antimalarial plus placebo. Chemoprophylaxis reduced the number of episodes of malaria and dactylitis, and increased mean haemoglobin values in this trial.

Authors' conclusions: It is beneficial to give routine malaria chemoprophylaxis in sickle cell disease in areas where malaria is endemic.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1.1
1.1. Analysis
Comparison 1 Chloroquine plus benzathine penicillin versus placebo, Outcome 1 Malaria episodes after 12 months of treatment.
2.1
2.1. Analysis
Comparison 2 Proguanil or pyrimethamine (data combined) versus placebo, Outcome 1 Death.
2.2
2.2. Analysis
Comparison 2 Proguanil or pyrimethamine (data combined) versus placebo, Outcome 2 Sickle cell crisis.
2.3
2.3. Analysis
Comparison 2 Proguanil or pyrimethamine (data combined) versus placebo, Outcome 3 Blood transfusion.
2.4
2.4. Analysis
Comparison 2 Proguanil or pyrimethamine (data combined) versus placebo, Outcome 4 Malaria infection.
2.5
2.5. Analysis
Comparison 2 Proguanil or pyrimethamine (data combined) versus placebo, Outcome 5 Hospital admission.
2.6
2.6. Analysis
Comparison 2 Proguanil or pyrimethamine (data combined) versus placebo, Outcome 6 Haemoglobin concentration.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Eke 2003 {published data only}
    1. Eke FU, Anochie I. Effects of pyrimethamine versus proguanil in malaria chemoprophylaxis in children with sickle cell disease: a randomized, placebo‐controlled, open‐label study. Current Therapeutic Research 2003;64(8):616‐25. - PMC - PubMed
Warley 1965 {published data only}
    1. Lewthwaite CJ. A trial of chemoprophylaxis in sickle‐cell anaemia. East African Medical Journal 1962;39(5):196‐9. - PubMed
    1. Warley MA, Hamilton PJ, Marsden PD, Brown RE, Merselis JG, Wilks N. Chemoprophylaxis of homozygous sicklers with antimalarials and long‐acting penicillin. British Medical Journal 1965;2(5453):86‐8. - PMC - PubMed

References to studies excluded from this review

Hendrickse 1966 {published data only}
    1. Hendrickse RG, Barnes PM. Sickle cell anaemia: report of a therapeutic trial. West African Medical Journal 1966;15(2):55‐64. - PubMed
Molineaux 1979b {published data only}
    1. Molineaux L, Gramiccia G. The Garki Project: research on the epidemiology and control of malaria in the Sudan savanna of West Africa. Geneva: World Health Organization, 1980.
Terlouw 2004 {published data only}
    1. Terlouw DJ, Desai MR, Wannemuehler KA, Kariuki SK, Pfeiffer CM, Kager PA, et al. Relation between the response to iron supplementation and sickle cell haemoglobin phenotype in preschool children in western Kenya. American Journal of Clinical Nutrition 2004;79(3):466‐72. - PubMed

Additional references

Adekile 1999
    1. Adekile AD. Haemoglobinopathies. In: Azubuike JC, Nkangineme KEO editor(s). Paediatrics and child health in a tropical region. Owerri, Nigeria: African Educational Services, 1999:195‐206. [ISBN. 978 ‐ 2411 ‐ 76 ‐ 0]
Adeloye 1971
    1. Adeloye A, Luzzatto L, Edington GM. Severe malarial infection in a patient with sickle‐cell anaemia. British Medical Journal 1971;2(759):445‐6. - PMC - PubMed
Aluoch 1997
    1. Aluoch JR. Higher resistance to Plasmodium falciparum infection in patients with homozygous sickle cell disease in western Kenya. Tropical Medicine & International Health 1997;2(6):568‐71. - PubMed
Ashley‐Koch 2000
    1. Ashley‐Koch A, Young Q, Olney RS. Sickle haemoglobin (HbS) allele and sickle cell disease: a HuGE review. American Journal of Epidemiology 2000;151(9):839‐45. - PubMed
Athale 1994
    1. Athale UH, Chintu C. Clinical analysis of mortality in hospitalized Zambian children with sickle cell anaemia. East African Medical Journal 1994;71(6):388‐91. - PubMed
Colbourne 1956
    1. Colbourne MJ, Edington GM. Sickling and malaria in the Gold Coast. British Medical Journal 1956;i(4970):784‐6. - PMC - PubMed
Fleming 1989
    1. Fleming AF. The presentation, management and prevention of crisis in sickle cell disease in Africa. Blood Reviews 1989;3(1):18‐28. - PubMed
Higgins 2005
    1. Higgins J, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Appendix 5b. www.cochrane.org/resources/handbook/hbook.htm (accessed 1 March 2006).
Jüni 2001
    1. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42‐6. - PMC - PubMed
Konotey‐Ahulu 1971a
    1. Konotey‐Ahulu FID. Malaria and sickle‐cell disease. British Medical Journal 1971;2(763):710‐1. - PMC - PubMed
Konotey‐Ahulu 1971b
    1. Konotey‐Ahulu FID, Serjeant G, White JM. Treatment and prevention of sickle cell crisis. Lancet 1971;2(7736):1255‐6. - PubMed
Leikin 1989
    1. Leikin SL, Gallagher D, Kinney TR, Sloan D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Pediatrics 1989;84(3):500‐8. - PubMed
Maharajan 1983
    1. Maharajan R, Fleming AF, Egler L. Pattern of infections among patients with sickle cell anaemia requiring hospital admission. Nigerian Journal of Paediatrics 1983;10:13‐7.
Molineaux 1979a
    1. Molineaux L, Fleming AF, Cornille‐Brogger R, Kagan I, Storey J. Abnormal haemoglobins in the Sudan savanna of Nigeria. III. Malaria, immunoglobulins and antimalarial antibodies in sickle cell disease. Annals of Tropical Medicine and Parasitology 1979;73(4):301‐10. - PubMed
Nwokolo 2001
    1. Nwokolo C, Wamebe C, Akinyanju O, Raji AA, Audu BS, Emodi IJ, et al. Mefloquine versus proguanil in short‐term malaria chemoprophylaxis in sickle cell anaemia. Clinical Drug Investigation 2001;21(8):537‐44.
Ogala 1999
    1. Ogala WN. Malaria. In: Azubuike JC, Nkanginieme KEO editor(s). Paediatrics and child health in a tropical region. African Educational Services, 1999:427‐37. [ISBN. 978 ‐ 2411 ‐ 76 ‐ 0]
Okuonghae 1992
    1. Okuonghae HO, Nwankwo MU, Offor E. Malarial parasitaemia in febrile children with sickle cell anaemia. Journal of Tropical Pediatrics 1992;38(2):83‐5. - PubMed
Otoo 1988
    1. Otoo LN, Snow RW, Menon A, Byass P, Greenwood BM. Immunity to malaria in young Gambian children after a two‐year period of chemoprophylaxis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1988;82(1):59‐65. - PubMed
Platt 1994
    1. Platt OS, Brambila DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. New England Journal of Medicine 1994;330(23):1639‐44. - PubMed
Review Manager 5 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Rogers 1978
    1. Rogers DW, Clarke JM, Cupidore L, Ramlal AM, Sparke BR, Serjeant GR. Early deaths in Jamaican children with sickle cell disease. British Medical Journal 1978;1(6126):1515‐6. - PMC - PubMed
Salako 2000
    1. Salako L. Malaria in Nigeria. Proceedings of the 31st Annual General and Scientific Meeting of the Paediatric Association of Nigeria; 2000 January 28; Abuja. Abuja: Paediatric Association of Nigeria, 2000.
Serjeant 1997
    1. Serjeant GR. Sickle‐cell disease. Lancet 1997;350(9079):725‐30. - PubMed
WHO 1990
    1. WHO Scientific Group on the Chemotherapy of Malaria. Practical chemotherapy of malaria: report of a WHO scientific group [meeting held in Geneva from 5 to 12 June 1989]. Technical Report Series 805. Geneva: World Health Organization, 1990. - PubMed
WHO 2000
    1. World Health Organization. Updated estimates of the frequency of the haemoglobin disorders in each country. www.who.ch/programmes/ncd/hgm/haemogl.htm (accessed May 2001).
WHO 2001
    1. Global Parnership to Roll Back Malaria. The use of antimalarial drugs: report of a WHO informal consultation, 13‐17 November 2000 [WHO/CDS/RBM/2001.33]. Geneva: World Health Organization, 2001.

Publication types